Management guidelines continue to identify metformin as initial pharmacologic antidiabetic therapy of choice for people with type 2 diabetes without contraindications, despite recent randomized trials that have demonstrated significant improvements in cardiovascular outcomes with newer classes of antidiabetic therapies. The purpose of this review is to summarize the current state of knowledge of metformin's therapeutic actions on blood glucose and cardiovascular clinical evidence and to consider the mechanisms that underlie them. The effects of metformin on glycaemia occur mainly in the liver, but metformin-stimulated glucose disposal by the gut has emerged as an increasingly import site of action of metformin. Additionally, metformin induces increased secretion of GLP-1 from intestinal L-cells. Clinical cardiovascular protection with metformin is supported by three randomized outcomes trials (in newly diagnosed and late stage insulin-treated type 2 diabetes patients) and a wealth of observational data. Initial evidence suggests that cotreatment with metformin may enhance the impact of newer incretin-based therapies on cardiovascular outcomes, an important observation as metformin can be combined with any other antidiabetic agent. Multiple potential mechanisms support the concept of cardiovascular protection with
| INTRODUCTION
The choice of treatments for type 2 diabetes is wider than ever before, and several drugs have now been shown to significantly reduce the risk of major adverse cardiovascular events (MACEs) and/or the risk of premature mortality in this population. Nevertheless, at the time of writing, influential diabetes management guidelines continue to identify metformin as initial antidiabetic pharmacotherapy of choice (in the absence of contraindications) more than 60 years after its first therapeutic administration to a person with diabetes. 1 It is important to place our knowledge of the actions of metformin within the current context of increased emphasis on the need to protect the cardiovascular system in type 2 diabetes. In this review, we provide a concise snapshot of current knowledge concerning the effects of metformin on glycaemia and clinical cardiovascular outcomes, together with a review of the diverse range of proposed mechanisms of action that underlie such effects.
| SEARCH STRATEGY
For this narrative review, we searched PubMed for articles on "metformin" and "cardiovascular," limited to "randomized controlled trial," in order to locate articles describing the effects of metformin on cardiovascular outcomes. Additional specific searches (eg, "microbiome")
were conducted to explore new data on the antihyperglycaemic mechanisms and potential cardiovascular mechanisms of metformin to capture latest findings. Review articles and authors' experience provided additional material.
| ANTIHYPERGLYCAEMIC MECHANISMS

| Systemic actions
The main systemic antihyperglycaemic action of metformin is a reduction of hepatic glucose production, due to a reduction in gluconeogenesis, although some (but not all) studies have identified enhanced insulin-mediated glucose uptake in muscle during treatment with metformin (see also Table 1 ). [2] [3] [4] [5] [6] [7] [8] [9] [10] The net result is a clinically significant Note. See text for references. reduction in fasting plasma glucose (FPG) that is similar to that seen with other agents. 1 At a cellular level, in both liver and muscle, the actions of metformin have been associated with activation of the enzyme, AMP kinase (AMPK), a sensor of energy homoeostasis. 11 Activation of AMPK results in a shift from energy-consuming activities (eg, lipid production and gluconeogenesis) to energy-sparing/generating activities (eg, glucose uptake and lipid oxidation). 12 The activation of AMPK is indirect:
an increase in the ration of AMP and ADP to ATP within the cell, in turn caused by a mild inhibition by metformin of oxidative phosphorylation, particularly respiratory complex I.
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Most people with type 2 diabetes display a paradoxical increase in glucagon levels during the postprandial state, rather than the decrease seen in normoglycaemic individuals. 14 Another cellular action described for metformin is an inhibition of cAMP accumulation, which leads to reduced activity of adenylate cyclase and a functional inhibition of the stimulatory effect of glucagon on hepatic glucose production. 15 Incretin-based therapies and glucagon antagonists (currently in clinical development for the treatment of type 2 diabetes) improve glucose homoeostasis at least in part by suppression of glucagon signalling pathways: this action of metformin may therefore have important functional significance. 
| Intestinal disposal of glucose
Observations on increased uptake of metformin into the intestines of rodents were made first in the early 1990s. [16] [17] [18] More recently, a randomized trial in newly diagnosed type 2 diabetes patients showed that metformin increased glucose uptake into the intestine by twofold to threefold (depending on the part of the intestine studied), while rosiglitazone had limited effect. 19 Experimental data from the same publication confirmed that the uptake occurred in the mucosal layer, as described previously. 19 A retrospective evaluation of patients who underwent 18 F-fluorodeoxyglucose (FDG) PET-CT scans for diagnostic purposes also showed that metformin but not insulin or sulphonylurea increased FDG uptake into all parts of the intestine. 20 Finally, a recent pilot study in 12 people with diabetes or metabolic syndrome showed that the uptake of metformin into the colon was 150-fold greater than into the plasma. 21 The intestinal uptake of metformin appears to be mediated by a range of cation transporters (reviewed elsewhere 22 ).
Genetic variations in these proteins have been associated with altered tissue uptake of metformin, but this effect may be more important for modulating the gastrointestinal side effects of metformin than altering its effects on plasma glucose. 22, 23 Metformin may also alter glucose uptake into the gut via effects on glucose transporters, including SGLT1 and GLUT transporters.
24,25
Increased intestinal glucose uptake during treatment with metformin appears to be functionally significant, as it is accompanied by an increase in anaerobic glucose metabolism, sufficient in magnitude to account for a clinically significant proportion of the overall antihyperglycaemic action of metformin. [16] [17] [18] It has been suggested that this anaerobic metabolism, which generates relatively little ATP, effectively amounts to a futile cycle of glucose metabolism that may contribute to weight loss commonly observed during metformin treatment. 22 Importantly, effects of metformin on GLP-1 secretion appear well maintained, as shown by the 18-month CAMERA study, where placebo-subtracted total GLP-1 was increased during metformin treatment, by 21% at 6 months, 27% at 12 months, and 19% at 18 months.
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These changes were independent of changes in glycaemia or weight and independent of other cardiometabolic confounders.
| The intestinal microbiome
The gut microbiome contains more than 1000-fold more genes than the human genome, 40 and new research is elucidating its role in health and disease. Alterations in gut microbiota have been associated with dysglycaemia, including on people with prediabetes. 41 Treatment with type 2 diabetes patients with metformin has been shown to alter the relative abundance of individual microbial species within the gut, particularly increasing the number of bacteria that produce short-chain fatty acids [42] [43] [44] [45] or reduce the abundance of bacteria producing branched amino acids associated with insulin resistance. 46 A recent randomized trial demonstrated altered gut microbiota during metformin treatment of antidiabetic drug-naïve type 2 diabetes patients. 47 Interestingly, this study confirmed the effect on microbiota by reproducing the effect in patients switched from placebo to metformin and confirmed an association with effects on glycaemia by demonstrating improved glucose tolerance in rodents that received transfers of faecal samples from patients at baseline and after treatment.
Addition of a commercially available modulator of the microbiome to metformin (claimed to increase the provision of short-chain fatty acids by gut bacteria) improved the gastrointestinal tolerability of metformin in a randomized placebo-controlled trial. 48 Experimental data suggest that alterations to the gut microbiome in rodents by metformin treatment modulate a glucose-sensing glucoregulatory system mediated via expression of the sodium-glucose transporter, SGLT1, in the upper intestine. 49 Accordingly, the gut microbiome appears to be an important, if currently incompletely understood, site of action of metformin. This action of metformin may be relevant not only to its antihyperglycaemia effects but also to other pathologies including disorders of the immune system and cancer. 50 Table 2 summarizes details of the three randomized controlled trials that provide the most important evidence for cardiovascular protection with metformin. [51] [52] [53] The principal evidence for cardiovascular protection by metformin arises from the UK Prospective Diabetes Study (UKPDS 34). 51 In this study, 1704 overweight patients (>120% ideal body weight) within the overall UKPDS population of 4075
| CARDIOVASCULAR PROTECTION WITH METFORMIN
| Overview of evidence for cardiovascular protection
patients were randomized to a diet control intervention (the "conventional" treatment policy of the time) or to intensive blood glucose control with metformin, glibenclamide (glyburide), chlorpropamide, or The composite macrovascular endpoint contained recurrent cardiovascular events, including nonfatal myocardial infarction, nonfatal stroke, arterial revascularization, death from a cardiovascular cause, and death from any cause. 
54
This main analysis of the study reported 20 years ago, 51 yet some myths about the trial persist. 55 For example, some contend that the evaluation of metformin was conducted in a substudy (eg, in this article, 56 from 2017) but metformin was included within the primary randomization of the trial, although restricted to overweight participants. Second, the trial is regarded as small and has been so described in a transatlantic management guideline for type 2 diabetes. 57 This is true, compared with the current generation of outcomes trials for new antidiabetes agents, which mostly have trial populations of several thousand patients. 1 Nevertheless, it is worth noting that, while the population of 342 patients randomized to metformin is often cited in this context, the number of patients randomized increases to 753 when the diet-treated control group is included, as it should be. 51 Two other prospective randomized trials ( including in subgroups with CHF or CKD, consistent with the studies described above. 83 The current transatlantic guideline for the management of type 2 diabetes 1 notes that a meta-analysis of randomized trials that evaluated metformin 84 did not demonstrate a reduction in cardiovascular disease.
Overall, the results of meta-analyses of the effects of metformin vs other diabetes medications on clinical outcomes have been conflicting. [84] [85] [86] These meta-analyses included mostly short-term studies, while the cardiovascular benefit for metformin vs the control population in the UKPDS did not emerge until after several years of treatment.
Finally, metformin did not significantly reduce the incidence of microvascular complications in the randomized or posttrial phases of the UKPDS.
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4.2 | Mechanisms of metformin proposed to protect the cardiovascular system Table 1 provides an overview of mechanisms of action that have been reported to explain the effects of metformin on glycaemia and on the cardiovascular system. These mechanisms are explained briefly below.
| Endothelial function and haemostasis
The vascular endothelium is intimately involved in the regulation of tes. [87] [88] [89] [90] [91] [92] Other studies have demonstrated potentially beneficial effects of metformin on other components of the haemostatic system, such as factors VII and XIII. 93, 94 It has been suggested that an overall improvement in thrombolysis may underlie the reduction of ischaemia-reperfusion injury by metformin in animal models or myocardial infarction and that prospective clinical study of this phenomenon is warranted. 95, 96 Metformin also reduced the expression of markers of activation of the endothelium (an early step in atherogenesis) 87 
| Cellular antiatherogenic effects
The binding of monocytes to the activated endothelium is an early event in the development of atherosclerosis. The subsequent infiltration of monocytes into the vascular wall, and their differentiation into macrophages, sets the scene for the development of the mature atherosclerotic plaque. Recent experimental data have shown that metformin inhibited the conversion of monocytes to macrophages and inhibited angiotensin II-induced atherosclerotic plaque formation, in a strain of genetically engineered mice prone to atherosclerosis. 112 Reduced infiltration of macrophages into the vascular wall, with reduced secretion of inflammatory cytokines, was also observed in a rabbit model of atherogenesis. 113 The effect on angiogenesis in one of these studies 114 and in and in other experimental studies 115, 116 was associated with stimulation of the AMPK/inhibition of mTOR by metformin, which suggests that such a mechanism may be of relevance to the clinical therapeutic action of metformin. Other potentially vascular protective mechanisms described for metformin in experimental studies include reduced cholesterol uptake 117 
| Glycoxidation
Chronic exposure to hyperglycaemia causes sugar moieties to become attached to proteins, which can impair their function, and is believed to represent an important cellular mechanism for the development of long-term complications of diabetes. 126 The formation of these advanced glycation end products (AGE) activates a specific receptor (RAGE), which in turn promotes a toxic combination of oxidative stress and inflammation, a process that has been termed "glycoxidation."
Metformin interacts chemically with key α-dicarbonyl intermediates in the formation of AGE (to form triazepinone compounds) and neutralizes them, thus inhibiting the formation of AGE. 127 Two studies suggest that this phenomenon may be clinically relevant. First, dose-dependent reductions in the levels of two of these dicarbonyls (glyoxal and methylglyoxal) were seen during metformin treatment in people with type 2 diabetes. 128 Second, the presence of triazepinones has been demonstrated in the urine of metformintreated type 2 diabetes patients, suggesting that metformin does indeed neutralize these toxic metabolites in the therapeutic setting. 129 Other clinical evidence further suggests a potentially beneficial effect of metformin on parameters related to oxidative stress and inflammation in people with type 2 diabetes. This includes improvements in the levels of metabolites believed to act as antioxidant defence mechanisms, 130 reduced peroxidation of circulating lipids (oxidization of lipids increases their atherogenicity), 131 and reduced production superoxide free radicals, which is likely related to the mild inhibition by metformin of respiratory complex I (see above). 
| Glycaemia
The so-called mega-trials, such as ACCORD, VADT, ADVANCE, etc, did not demonstrate a cardiovascular benefit for intensive vs moderate glycaemic control; however, a large meta-analyses of these and other studies showed that tight glycaemic control (difference in HbA1c for active comparators vs controls of 0.9%) reduced the relative risk of coronary heart disease events by 15% and of nonfatal myocardial infarction by 17%. 133 An observational study in a cohort of metformin initiators for type 2 diabetes showed that a larger initial fall in HbA1c and maintenance of lower HbA1c levels for the first 6 months of therapy were associated with improved cardiovascular outcomes. 134 Such a benefit may, in principle, apply to any antihyperglycaemic agent, as long as it did not bring side effects deleterious to the cardiovascular system.
Indeed, observational/epidemiologic follow-up studies to the UKPDS (sulphonylurea/insulin vs diet in people with type 2 diabetes) 54 and the Diabetes Control and Complications Trial (more vs less intensive application of insulin in people with type 1 diabetes) 135 showed that initial randomization to more vs less intensive glycaemic control was associated with reduced risk of adverse cardiovascular outcomes many years after the end of randomized treatment. This was despite the fact that average HbA1c levels had become similar for the groups previously randomized to each treatment arm. These "legacy effects" in populations with relatively early diabetes suggest that hyperglycaemia at this time sets in motion long-term adverse effects on cardiovascular tissues and that achievement of glycaemic control is especially important for cardiovascular protection in this population, as long as this can be achieved safely and without excessive hypoglycaemia. 1 
| CURRENT AND FUTURE PERSPECTIVES
Improvements in cardiovascular outcomes in type 2 diabetes patients randomized to SGLT2 inhibitors and some members of the GLP-1 agonist class (reviewed elsewhere [136] [137] [138] ) have been received with considerable (and justified) excitement. This review has sought to review outcomes and mechanisms for metformin, a much older antidiabetes medication, and indeed one that has been clinically available for 60 years. 59 The key to a successful outcome in type 2 diabetes is successful individualization of therapy, matching the right regimen to the patient. The era of regulator-mandated cardiovascular outcomes trials is a recent phenomenon, and the randomized outcomes trials with metformin described above predate this era. Modern cardiovascular outcomes trials usually employ a primary outcome of three-point MACEs, with hierarchical statistical analysis protocols, rather than the more complex designs (with a larger number of endpoints) used by the UKPDS and other studies. Thus, it is difficult to compare side by side the outcomes trials with metformin with the studies of the modern era in diabetes research, and we lack a truly definitive randomized outcomes trial with metformin that employs a modern design. A review of experience from trials in heart failure has also emphasized the importance of the use of a definitive trial design to assess important clinical outcomes, 139 and the changing nature of trials in diabetes tends to favour newer agents over older generic agents such as metformin. Accordingly, further evaluation of the cardiovascu- Dr Salim Mihson Alruba, a leading diabetes physician in Iraq, contributed importantly to the ideas behind this article but sadly passed away before its preparation. We, the authors, acknowledge his contribution, and our thoughts and prayers are with his family. All authors reviewed and commented on the manuscript, and all approved the final version. 
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